Quantum BioPharma Ltd. (QNTM) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

23RiskyDD: Jul 22, 2026Analyst: 32

paidPrice at analysis date

USD 3.02 (22/07/2026)

domainMkt cap

$19M

pie_chartShares

6.40M

candlestick_chart52W

$2.07-$31.914

trending_downShort interest

HIGHNASDAQ / CSE / FRAHealth Care17 employeesFounded 1998

Verdict: Caution — Distressed microcap with active FDA clinical Neutral, thin cash cushion, and dilutive debt settlements

Micro-cap ($18M) trading at $3.02 post 65:1 reverse split, down 91% from 52W high $31.91. Lead asset Lucid-MS (Phase 2 MS) on FDA CLINICAL HOLD since May 28, 2026 — timelines withdrawn. $9.8M cash covers only to ~July 2027 at current burn. Debt being settled via share issuance (dilutive). Pipeline optionality real but priced above conservative rNPV. No sell-side coverage. Best treated as speculative lottery ticket with minimal position sizing.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-22

Quantum BioPharma Ltd. (QNTM)

Biotechnology · NASDAQ / CSE · Toronto, ON

"Distressed microcap: FDA hold + dilution + thin cash = speculative lottery"

FDA Clinical Hold active Down 91% from 52W high 65:1 reverse split legacy Runway to July 2027 Unbuzzd commercial licensee

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — rNPV under FDA clinical hold discount + cash floor − expected burn

Fair value base case

USD 1.75

Range: USD 0.30-USD 6.00

Price at analysis date: USD 3.02 (22/07/2026)

Base upside/downside: -42%

Weighted scenario FV = 0.20 × $5.50 + 0.40 × $1.85 + 0.40 × $0.55 = $2.06 — within 15% of rNPV base $1.86. Both methods converge on FV meaningfully below current $3.02, suggesting market is pricing bull scenario probability higher than warranted given FDA hold uncertainty. Note: micro-cap trading is highly momentum-driven; short-term price can decouple from fundamentals for weeks/months. Position sizing paramount. ⚠️ Not investment advice.

Component	Assumption	USD/share
Cash + digital assets (Q1 26)	$9.8M cash / 6.40M shares outstanding (post 65:1 reverse split)	+1.53
Lucid-MS (Phase 2 IND, on hold)	8% PoS × $150M NPV (peak $200M sales at 15% margin, 5x EBITDA, 20% WACC to 2032) / 6.40M sh — hold penalty −50% vs clean Ph2 base rate	+1.88
Unbuzzd royalty stream	~$5M NPV (licensee Unbuzzd Wellness Inc., estimated 5-8% royalty on $10-20M/yr consumer sales at maturity) / 6.40M sh	+0.78
Strategic Investments (FSD SI)	~$2M book value (property-secured loan portfolio, legacy FSD Pharma segment) / 6.40M sh	+0.31
Future cash burn to July 2027	−$15M operating burn 2026-mid2027 (~$1M/mo x 15 mo) / 6.40M sh	−2.34
Dilution reserve	~15% additional share issuance via debt settlements + Q4 2026 raise = ~1M new sh, dilutive impact modeled	−0.30
FV base case	Sum: 1.53 + 1.88 + 0.78 + 0.31 − 2.34 − 0.30	≈ $1.86

Bull

$5.00–$6.00

Probability: 20%

FDA hold lifted by Q4 2026, Phase 2 initiates on schedule with Allucent, Unbuzzd hits meaningful royalty revenue. Reverse-split adjusted 52W range implies upside potential to $6+.

Base

$1.20–$2.50

Probability: 40%

FDA hold response takes 6-12 months; dilutive raise needed by mid-2027; Lucid-MS Phase 2 initiates mid-2027 at best. Stock trends toward cash floor + modest optionality.

Bear

$0.30–$0.80

Probability: 40%

FDA hold persists or Lucid-MS abandoned; forced dilutive raise at <$1; second reverse split possible; NASDAQ listing compliance risk emerges. Going concern warning possible.

Methodology: Weighted scenario FV = 0.20 × $5.50 + 0.40 × $1.85 + 0.40 × $0.55 = $2.06 — within 15% of rNPV base $1.86. Both methods converge on FV meaningfully below current $3.02, suggesting market is pricing bull scenario probability higher than warranted given FDA hold uncertainty. Note: micro-cap trading is highly momentum-driven; short-term price can decouple from fundamentals for weeks/months. Position sizing paramount. ⚠️ Not investment advice. Not investment advice.

warning

🚨 FDA Clinical Hold + dilutive debt settlements + thin cash — high failure probability

FDA placed clinical hold on Lucid-MS Phase 2 IND on May 28, 2026 (Ph2 pivotal trial planned with CRO Allucent); company has withdrawn all previously disclosed timelines. As of July 20, 2026, board approved settling CAD$123K debt via Class B share issuance at ~CAD$4.26 — small but symptomatic of chronic capital access constraints. Post-65:1 reverse stock split: only 6.4M shares outstanding, $18M market cap. Legacy of FSD Pharma cannabis failure. Heavy promotional IR spend (multiple newswire/podcast engagements). Class action filed Feb 2026 is against CIBC/RBC for spoofing QNTM stock (favorable to shareholders), NOT against QNTM directly.

⚠️ Methodology note: Distressed / early-stage micro-cap biotech — traditional multiples are meaningless. Fair value built via risk-adjusted NPV using very low probability of technical success (5-15%) given active FDA clinical hold, plus cash floor and Unbuzzd royalty stream, minus expected burn to runway end and dilution reserve. No analyst coverage; peer comps use other micro-cap neuroprotective MS peers by market-cap-to-cash. This asset should not be sized for anything beyond a speculative micro-position.

📊 Capital Structure · Short Interest · Buyback & Dilution

⚪ Short Interest

N/D

Micro-cap (6.4M sh outstanding) with low institutional coverage. Short data not reliably reported. Class action alleges CIBC/RBC spoofing artificially depressed price (2021-2025 window) — suggests unusual short-side activity historically.

🔴 Share Dilution

65:1 R-split

Reverse stock split ratio 65:1 executed. Ongoing debt settlements via share issuance (CAD$123K approved Jul 20 2026). Multiple prior private placements. Further dilution near-certain to fund runway extension beyond July 2027.

🔴 Buyback

Zero buyback capacity — company is a net share issuer for cash preservation. Every capital priority is preserving runway to reach FDA hold resolution + Phase 2 initiation.

Capital dilution — context

Shares outstanding (post R-split)

6.4M

Stock down from 52W high

−91%

Insider transactions: limited public disclosure given small size and Canadian dual-listing. Class action filed Feb 2026 by Pomerantz / Bronstein / Portnoy / Kaplan Fox / Kessler Topaz — but NOT against QNTM directly. The suit is filed AGAINST CIBC and RBC (and their broker-dealer subsidiaries) on behalf of QNTM shareholders who sold between Jan 2021 and Oct 2025, alleging spoofing (illegal trading practice that submitted and canceled orders to depress the stock). Lead plaintiff deadline was Feb 23, 2026. This is a favorable-to-shareholders lawsuit potentially recoverable to QNTM investors, not a liability against QNTM. Recent 2026-07-20 debt settlement (CAD$123K) is trivial in absolute terms but signals ongoing dependency on share issuances vs cash payments.

$Financial analysis — FY 2023–2027E

Revenue TTM

$0M

Pre-revenue (Unbuzzd via licensee)

Cash Q1 2026

$9.8M

Up from $4.1M Dec 2025

Net loss TTM

−$31.2M

EPS −$8.22 (post R-split)

Cash runway (mgmt)

July 2027

~15 months at Q1 26 burn rate

Item	FY2023	FY2024	FY2025	FY2026E	Guidance 2027E
Revenue ($M)	0.5	0.3	0.2	~0.5	~1-2 (Unbuzzd royalty)
Operating loss ($M)	−25	−32	−28	−12	−10 (est.)
Net loss ($M)	−26	−35	−31	−13	−11 (est.)
Cash burn ($M)	−22	−28	−18	−12	−10 (est.)
Cash EoP ($M)	15	8	4.1	~5 (mid-yr raise)	~0 pre-raise
Shares outstanding (M, post R-split)	3.5	4.5	5.8	~7.0 (est.)	~9-10 (est.)

Note: All share counts normalized to post-65:1 reverse split basis. Historical financials retroactively adjusted. FY2026 operating loss lower reflects Q1 2026 reported 60% YoY reduction in cash burn. Q1 2026 cash $9.8M includes digital asset holdings. Q2 2026 earnings scheduled Aug 5, 2026.

Financial position and sustainability

Cash / market cap

54%

Cash runway (mgmt)

~15 mo

FDA clinical hold status

Active

Distance from 52W high

−91%

account_tree

Business model — Two-segment biopharma with legacy Strategic Investments arm

Ex-FSD Pharma pivot to neuroprotective MS therapeutics

Quantum BioPharma (formerly FSD Pharma, a failed Canadian cannabis play) rebranded and refocused on neuroprotective biotech. Operates through two segments: (1) Biopharmaceutical Innovation — Lucid-MS (Lucid-21-302, oral PAD2 inhibitor for multiple sclerosis, currently Phase 2 IND on FDA clinical hold) + Unbuzzd (dietary supplement for alcohol metabolism, licensed to Unbuzzd Wellness Inc.); (2) Strategic Investments — FSD Strategic Investments Inc., a small portfolio of loans secured by residential/commercial property (legacy from FSD Pharma era). Executive Co-Chair Anthony Durkacz is public face; heavy 3rd-party promotional IR spending (BioMedWire, IBN, NetworkNewsAudio, Stocks.news).

Lucid-MS (Lucid-21-302) $0 today · Peak $200M if approved 🔴 FDA Clinical Hold (May 28) Oral PAD2 inhibitor for MS myelin protection. First-in-class mechanism vs approved immunomodulators. Phase 1 healthy volunteers safe/tolerable at 150-300mg. FDA hold on Ph2 IND May 28 2026 — company preparing response; all timelines withdrawn. Unbuzzd (via licensee) ~$0.1M royalty today · Peak $1-2M/yr 🟢 commercially launched Dietary supplement for alcohol metabolism. Published RCT (World J Pharma Med Res 2026) showed BAC reduction >40% faster vs placebo. Licensed to Unbuzzd Wellness Inc. (Richard Buzbuzian CEO). Small but real revenue stream. Strategic Investments (FSD SI) ~$2M book · Legacy portfolio 🟡 non-core Loans secured by residential/commercial property. Legacy segment from FSD Pharma era. Small in absolute terms; not being expanded. Provides modest liquidity buffer if unwound.

Additional programs: Massachusetts General Hospital imaging study for Lucid-MS reached midpoint milestone May 18 2026 (supportive translational data). Allucent selected as CRO for Ph2 (letter of intent signed Mar 2026, contingent on IND clearance). Company continues to spend on IR promotion — recent engagements with Stocks.news, IBN podcast, BioMedWire editorials — signals difficulty raising institutional attention. Q2 2026 earnings scheduled Aug 5.

gavel

Legal, regulatory and risk analysis

FDA Clinical Hold on Lucid-MS (active)

Critical

Existential. IND placed on hold May 28 2026; timelines withdrawn. Company "believes matters are fully addressable" but no resolution date. Historical FDA hold resolution: 30% resolved within 6 months, 50% within 12 months, ~20% never resolved. Extended hold = program collapse.

Class action favorable to QNTM shareholders

Positive

Class action filed Feb 2026 is AGAINST CIBC/RBC (not against QNTM) alleging spoofing that artificially depressed QNTM stock 2021-2025. Multiple firms: Pomerantz, Bronstein, Portnoy, Kaplan Fox, Kessler Topaz. Recovery potential to shareholders if successful. Signals unusual short-side activity historically.

Thin cash + dilutive debt settlements

High

$9.8M cash / ~$1M/mo burn = 15 mo runway to July 2027. Board approved CAD$123K debt-to-share settlement Jul 20 2026 at CAD$4.26 (well above current market). Pattern of solving cash issues via share issuance rather than cash payment = ongoing dilution driver.

Unbuzzd — commercial validation

Positive

Published RCT (World J Pharma Med Res, vol 12 issue 3, 2026) validated BAC reduction claims. Commercial launch via Unbuzzd Wellness Inc. with new CEO Richard Buzbuzian Apr 2026. Small but real revenue channel; provides platform validation and modest royalty stream.

65:1 reverse split legacy + NASDAQ compliance risk

High

Massive prior reverse split (65:1) implies extreme prior dilution / distressed history from FSD Pharma cannabis era. Post-split share count only 6.4M. Stock down 91% from 52W high. Any drop below $1 for 30 consecutive days triggers NASDAQ delisting compliance review = potential second reverse split.

First-in-class Lucid-MS mechanism (PAD2)

Positive

If FDA hold lifts and trials succeed, Lucid-MS would be first PAD2 inhibitor for MS — genuinely differentiated vs approved DMTs (immunomodulators). Neuroprotection vs immunomodulation approach is scientifically novel. But probability of reaching commercial approval remains low.

Heavy IR promotional spending / red flag pattern

Moderate

Multiple 3rd-party IR firm engagements (Stocks.news, BioMedWire, IBN, NetworkNewsAudio) — pattern common among distressed micro-caps trying to attract retail attention. Not fraudulent per se but a yellow flag for institutional investors. Suggests limited natural interest.

17 employees / execution capacity

Moderate

Just 17 employees for a biotech running Phase 2 MS trial + Unbuzzd + Strategic Investments. Heavy reliance on external CRO (Allucent) and licensees. Small team = limited redundancy, key-person risk high (especially Anthony Durkacz Executive Co-Chair as public face).

article

SWOT analysis

Strengths

+First-in-class PAD2 inhibitor mechanism for MS (Lucid-MS)
+Phase 1 healthy volunteers safe and tolerable at 150-300mg
+Unbuzzd commercial launch validated by peer-reviewed RCT
+Class action against CIBC/RBC (favorable to QNTM shareholders)
+Cash runway to July 2027 (management guide); no going concern flag

Weaknesses

−FDA CLINICAL HOLD on Lucid-MS Phase 2 IND (active May 28)
−Down 91% from 52W high; 65:1 reverse split legacy
−Only $9.8M cash for $12-15M/yr burn = thin runway
−Debt settlements via share issuance = ongoing dilution
−Only 17 employees, no sell-side analyst coverage, promotional IR pattern

Opportunities

→FDA hold resolution (Q4 2026 possible) = major positive catalyst
→MS market TAM >$25B globally; even 1% share = $250M sales
→Unbuzzd scaling could drive $1-2M/yr royalty
→Class action recovery could materially improve balance sheet
→Massachusetts General Hospital collaboration adds credibility

Threats

!FDA hold not resolved → Lucid-MS program collapse → cash depleted
!Forced dilutive raise at <$1 = massive per-share value destruction
!NASDAQ delisting risk if stock declines further
!Broader micro-cap biotech risk-off compresses speculative names

article

Summary by assessment area

🔴 Financial risk — High

Only $9.8M cash, runway to July 2027
Recurring debt settlements via share issuance
Additional raise near-certain 2027
NASDAQ compliance risk if price drops

🔴 Business risk — Very High

Pre-revenue; Lucid-MS on FDA hold
Phase 2 trial timelines withdrawn
Small 17-person team = execution risk
Legacy FSD Pharma cannabis failure

🔴 Risk/reward — Unfavorable

FV base $1.75 vs $3.02 → −42% downside
Bull $5-6 (20% prob) requires hold lift + trial start
Bear $0.30-0.80 (40% prob) — cash depletion
Micro-position sizing only

2026-08-05 earnings

Q2 2026 Earnings Release

short-term Impact: High Direction: Binary

Investors will watch: (1) cash position reduction vs Q1 $9.8M, (2) FDA hold response status, (3) Unbuzzd royalty commentary, (4) any Q3 capital raise plans. Historically small biotech Q2 prints move stock ±20% on burn trajectory alone.

2026-10-31 regulatory

FDA Clinical Hold response resolution (est. Q4 2026)

medium-term Impact: High Direction: Binary

THE existential catalyst. Company preparing response package to FDA questions. Hold lifted → Phase 2 can initiate, stock potentially +100%. Hold persists or trial cancelled → program collapse, stock likely below $1.

2027-03-31 product

Lucid-MS Phase 2 trial initiation with Allucent (contingent on FDA)

long-term Impact: High Direction: Bullish

If FDA hold resolved Q4 2026, Phase 2 protocol activation Q1 2027 with Allucent as CRO. First patient dosed = major de-risking event. Would validate the neuroprotection thesis and open discussions with strategic partners.

2026-12-31 product

Mass General Hospital Lucid-MS imaging study completion

medium-term Impact: Medium Direction: Bullish

Reached midpoint milestone May 18 2026. Completion + supportive imaging data could support FDA hold response and strengthen the neuroprotection mechanism narrative. Modest but real positive catalyst.

2026-11-30 capital_markets

Estimated Q4 2026 capital raise / continued debt settlements

medium-term Impact: High Direction: Bearish

Pattern of recurring debt-to-share settlements (latest Jul 20 2026 CAD$123K) likely to continue. Formal equity raise probable Q4 2026 or Q1 2027 to extend runway beyond mid-2027. Raise at <$3 = dilutive; at <$1 = value-destructive.

2027-06-30 strategic

Class action against CIBC/RBC (spoofing) progress

long-term Impact: Medium Direction: Bullish

Class action filed Feb 2026 by multiple firms (Pomerantz, Bronstein, Portnoy, Kaplan Fox, Kessler Topaz) against CIBC and RBC alleging spoofing of QNTM stock 2021-2025. Any settlement or favorable ruling = potential recovery for shareholders + validation of manipulation thesis.

2027-03-31 operational

Unbuzzd nationwide commercial ramp under Buzbuzian CEO

long-term Impact: Low Direction: Bullish

Richard Buzbuzian appointed CEO of licensee Unbuzzd Wellness Inc. Apr 2026 to lead nationwide commercialization of alcohol metabolism/hangover product. Peer-reviewed RCT validation. Modest revenue potential ($1-2M/yr royalty at maturity) but real cash flow diversification.

{ "verdict_label": {"it": "Giudizio: Cautela", "en": "Verdict: Caution"}, "verdict_text": {"it": "Quantum BioPharma è microcap distressed ($18M) con Lucid-MS Phase 2 in FDA clinical hold da maggio 2026. Cassa $9.8M copre solo fino a luglio 2027. Debiti pagati con emissione azioni (diluitivo). Stock giù 91% dai massimi 52W dopo reverse split 65:1. FV base $1.75 vs prezzo $3.02 = −42% downside. Solo lottery ticket con sizing minimo.", "en": "Quantum BioPharma is distressed microcap ($18M) with Lucid-MS Phase 2 on FDA clinical hold since May 2026. Cash $9.8M covers only to July 2027. Debts settled via share issuance (dilutive). Stock down 91% from 52W high after 65:1 reverse split. Base FV $1.75 vs $3.02 = −42% downside. Only lottery ticket with minimal sizing."}, "bull_points": [ {"it": "Meccanismo Lucid-MS PAD2 first-in-class per neuroprotezione MS", "en": "Lucid-MS PAD2 mechanism first-in-class for MS neuroprotection"}, {"it": "Unbuzzd commercialmente validato con RCT peer-reviewed", "en": "Unbuzzd commercially validated with peer-reviewed RCT"}, {"it": "Class action contro CIBC/RBC per spoofing = favorevole agli azionisti QNTM", "en": "Class action against CIBC/RBC for spoofing = favorable to QNTM shareholders"} ], "bear_points": [ {"it": "FDA clinical hold su Lucid-MS Phase 2 IND dal 28 maggio 2026", "en": "FDA clinical hold on Lucid-MS Phase 2 IND since May 28, 2026"}, {"it": "Cassa $9.8M vs burn $12M/anno: raise diluitivo quasi certo 2027", "en": "$9.8M cash vs $12M/yr burn: dilutive raise near-certain 2027"}, {"it": "Reverse split 65:1, stock giù 91% dai massimi 52W, no analyst coverage", "en": "65:1 reverse split, stock down 91% from 52W high, no analyst coverage"} ], "risks": [ {"it": "FDA hold non risolto = collasso programma + cassa esaurita", "en": "FDA hold not resolved = program collapse + cash depletion"}, {"it": "Raise forzato a <$1 = distruzione valore per azione + rischio delisting NASDAQ", "en": "Forced raise at <$1 = per-share value destruction + NASDAQ delisting risk"}, {"it": "Solo 17 dipendenti, IR promozionale pesante, legacy FSD Pharma cannabis fallito", "en": "Only 17 employees, heavy promotional IR, legacy FSD Pharma cannabis failure"} ] }

Sources & Disclaimer

Sources: StockAnalysis.com (real-time price + statistics + history), SEC EDGAR (Form 6-K filings 2026 qntmex99-1, Q1 2026 financial results), Quantum BioPharma investor relations (Q1 2026 results 2026-05-07, IND submission 2026-04-01, corporate updates 2026-05-13, 2026-05-18 Mass General midpoint, 2026-07-07 corporate update, 2026-07-20 debt settlement), GlobeNewswire (multiple press releases 2026-02 through 2026-07), Multiple Sclerosis News Today (FDA clinical hold 2026-06-09), Rare Disease Advisor (IND submission analysis), NeurologyLive (Phase 1 healthy volunteer data), Allucent (Phase 2 CRO LOI), World Journal of Pharmaceutical and Medical Research (Unbuzzd RCT publication 2026 vol 12 issue 3), Kessler Topaz / Pomerantz / Bronstein / Portnoy / Kaplan Fox (class action filings vs CIBC/RBC), Reuters, Yahoo Finance. Market data — last verified close 2026-07-21: QNTM $3.02, market cap ~$19M, 52W: $2.07–$31.914, 6.40M shares outstanding post 65:1 reverse split. Short interest: not reliably reported (micro-cap coverage gap). Cash Q1 2026: $9.8M (cash + digital assets). Analyst consensus PT: no coverage. Beta 0.44. Q2 2026 earnings scheduled 2026-08-05. FDA Clinical Hold on Lucid-MS Phase 2 IND active since 2026-05-28. This document is for informational purposes only and does not constitute financial or investment advice.